Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 2/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 2/20 | 0.39 |
| ▸ | CNR2 | P34972 | 2/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | TET3 | O43151 | 1/20 | 0.33 |
| ▸ | FBXL19 | Q6PCT2 | 1/20 | 0.33 |
| ▸ | CXXC5 | Q7LFL8 | 1/20 | 0.33 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.33 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.33 |
| ▸ | CXXC4 | Q9H2H0 | 1/20 | 0.33 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27572635 | 0.85 | ALDH1A1 (0.39) | CNR1CNR2OPRD1KCNH2PARP1 | |
| SCHEMBL6629960 | 0.85 | PARP1 (0.36) | CNR1CNR2OPRD1KCNH2PARP1 | |
| Hydrochloric Acid SCHEMBL6507301 | 0.84 | PARP1 (0.35) | CNR1CNR2OPRD1KCNH2PARP1 | |
| SCHEMBL7262771 | 0.78 | AVPR1A (0.43) | OPRL1OPRD1PARP1 | |
| SCHEMBL6632841 | 0.75 | MEN1 (0.44) | CNR2PARP1KMT2AALDH1A1MAPT | |
| SCHEMBL7257136 | 0.74 | OPRM1 (0.37) | OPRD1KCNH2PARP1 | |
| SCHEMBL6630805 | 0.74 | PARP1 (0.43) | HTR7PARP1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL6502264 | 0.74 | MEN1 (0.43) | CNR2PARP1KMT2AALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL6510200 | 0.73 | PARP1 (0.42) | HTR7PARP1ALDH1A1 | |
| SCHEMBL6509219 | 0.73 | GAA (0.41) | PARP1KMT2AALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1309594-B1 | BENZIMIDAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2004-12-15 | — | — | EP | claimed |
| EP-1399156-A2 | ALKYLIDENE PIRAZOLIDINEDIONE DERIVATIVES AND THEIR USE FOR TREATING DIABETES AND OBESITY | Applied Research Systems ARS Holding N.V. (AN) | 2004-03-24 | — | — | EP | claimed |
| WO-2002102359-A2 | ALKYLIDENE PYRAZOLIDINEDIONE DERIVATIVES AND USE FOR TREATING DIABETES AND OBESITY | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2002-12-27 | — | — | WO | claimed |
| US-20050032779-A1 | Benzimidazole derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2005-02-10 | — | — | US | disclosed |
| EP-1309594-B1 | BENZIMIDAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2004-12-15 | — | — | EP | disclosed |
| US-6794382-B2 | 6-OXO-5,6-DIHYDRO-4H-IMIDAZO(4,5,1-IJ)QUINOLINE DERIVATIVES AS INHIBITORS OF ADP-RIBOSYLTRANSFERASE; CARDIOVASCULAR, IMMUNOLOGICAL, RESPIRATORY SYSTEM, AND NEURODEGENERATIVE DISORDER TREATMENT | SANOFI-SYNTHELABO (FR) | 2004-09-21 | — | — | US | disclosed |
| US-20030203893-A1 | Benzimidazole derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2003-10-30 | — | — | US | disclosed |
| EP-1309594-A1 | BENZIMIDAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2003-05-14 | — | — | EP | disclosed |
| WO-2002012239-A1 | BENZIMIDAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-SYNTHELABO (FR) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032779-A1 | Benzimidazole derivatives, preparation and therapeutic use thereof | CBR3, CYP3A7, HDAC7 | MLYCD 2892/4885OPRL1 741/4885CNR1 20/4885 |
| US-20030203893-A1 | Benzimidazole derivatives, preparation and therapeutic use thereof | CBR3, HRH4, CBR1 | MLYCD 2393/4885OPRL1 677/4885CNR1 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.